SeaStar (ICU) director purchases 35,000 shares; weighted prices disclosed

Rhea-AI Filing Summary

SeaStar Medical Holding Corp (ICU) director Kenneth Van Heel reported open-market purchases totaling 35,000 shares across two days. On 08/26/2025 he acquired 25,000 shares at a weighted-average price of $0.8899, increasing his direct holdings to 39,400 shares. On 08/27/2025 he acquired 10,000 shares at a weighted-average price of $0.8565, raising his direct holdings to 49,400 shares.

The Form 4 shows these were non-derivative purchases and that no derivative securities were reported. The filing was submitted by an attorney-in-fact on 08/28/2025.

Positive

• Director purchases reported: Kenneth Van Heel acquired a total of 35,000 common shares on 08/26/2025 and 08/27/2025.
• Transparent pricing detail: Weighted-average prices disclosed ($0.8899 and $0.8565) with commitment to provide per-trade breakdowns upon request.

Negative

• None.

Insights

Financial Analyst

TL;DR: A director made modest open-market buys totaling 35,000 shares at sub-$1 prices; confirms direct insider accumulation.

The report documents non-derivative purchases by a director on 08/26/2025 and 08/27/2025 for a combined 35,000 shares at weighted-average prices of $0.8899 and $0.8565. Post-transactions direct beneficial ownership is reported at 49,400 shares. Transactions were disclosed on a Form 4 and executed via multiple tranches as noted in the explanations.

Corporate Governance Expert

TL;DR: Timely Form 4 disclosure shows director-level purchases and straightforward reporting; no derivatives or complex arrangements disclosed.

The filing identifies Kenneth Van Heel as a director and reports direct acquisitions only. The explanatory footnotes clarify weighted-average prices due to multiple trades. An attorney-in-fact signed the form. No amendments or additional arrangements are indicated in the document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Heel Kenneth

(Last) (First) (Middle)

C/O SEASTAR MEDICAL HOLDING CORPORATION

3513 BRIGHTON BLVD., SUITE 410

(Street)

DENVER CO 80216

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SeaStar Medical Holding Corp [ ICU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/26/2025		P		25,000	A	$0.8899(1)	39,400	D
Common Stock, par value $0.0001 per share	08/27/2025		P		10,000	A	$0.8565(2)	49,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Row 1, Column 4 is a weighted average price of $0.8899. These shares were purchased in multiple transactions at prices ranging from $0.885 to $0.89 inclusive. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price.

2. The price reported in Row 2, Column 4 is a weighted average price of $0.8565. These shares were purchased in multiple transactions at prices ranging from $0.8531 to $0.8599 inclusive. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ Eric Schlorff, as attorney-in-fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for SeaStar Medical (ICU)?

Director Kenneth Van Heel reported purchases of 25,000 shares on 08/26/2025 at a weighted-average price of $0.8899 and 10,000 shares on 08/27/2025 at a weighted-average price of $0.8565.

How many shares does Kenneth Van Heel beneficially own after these transactions?

The Form 4 reports 49,400 shares beneficially owned directly by Kenneth Van Heel following the reported purchases.

Were any derivative securities reported in this Form 4 for ICU?

No. Table II (derivative securities) contains no reported transactions; only non-derivative common stock purchases are listed.

Who filed the Form 4 and when was it signed?

The Form 4 was filed on behalf of the reporting person and signed by Eric Schlorff, as attorney-in-fact on 08/28/2025.